Replimune GroupFRA:7R8 -3.56%32 Shareholder Yield % is -4.31% as of Mar. 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 1,296 Biotechnology companies, Replimune Group ranks worse than 59.41% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Replimune Group's Shareholder Yield % was -4.31%.
Replimune Group (FRA:7R8) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Replimune Group Shareholder Yield % Related Terms
Replimune Group Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Replimune Group's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:7R8 vs AVTX, KURA, SANA: Shareholder Yield % Comparison
For the Biotechnology subindustry, Replimune Group's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Replimune Group Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Replimune Group's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Replimune Group's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Replimune Group (FRA:7R8) has a Shareholder Yield % of -4.31% as of Mar. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Replimune Group and its competitors. According to the industry distribution chart, Replimune Group ranks #770 out of 1296 companies in the Biotechnology industry, placing it in the top 59.4%.
Is Replimune Group's Shareholder Yield % too high?
Replimune Group's current Shareholder Yield % is -4.31%. Based on the distribution chart, Replimune Group ranks #770 out of 1296 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's Shareholder Yield % compare to AVTX and KURA?
According to the Biotechnology industry distribution chart, Replimune Group ranks #770 out of 1296 companies for Shareholder Yield %. This places Replimune Group in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Replimune Group and its competitors. Replimune Group's current Shareholder Yield % is -4.31%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current Shareholder Yield % of -4.31%. The current Shareholder Yield % is -4.31%. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current Shareholder Yield % is -4.31% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score
Get the complete analysis for FRA:7R8
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7R8 has been successfully added to your 
